文献速递糖尿病

筛查利钠肽水平可预测无已知心衰的1型和2型糖尿病患者的心衰和死亡

Screening Natriuretic Peptide Levels Predicts Heart Failure and Death in Individuals With Type 1 and Type 2 Diabetes Without Known Heart Failure.
PubMed 文献 · Diabetes Care · 2025-01-01

本研究基于Optum Market Clarity数据库,纳入116,466例无已知心衰的1型或2型糖尿病成人,分析利钠肽(NP)水平与心衰发生或死亡的关系。随访至7年,约39.6%的1型糖尿病和42.3%的2型糖尿病患者BNP≥50 pg/mL或NT-proBNP≥125 pg/mL。调整后Cox模型显示,NT-proBNP升高与心衰或死亡风险显著增加相关,支持在糖尿病患者中开展NP筛查进行心衰风险评估。

要点

  • 在无已知心衰的糖尿病患者中,约四成患者NP水平升高。
  • NT-proBNP 125-300 pg/mL和>300 pg/mL均与心衰或死亡风险增加独立相关。
  • NP筛查有助于识别可从疾病修饰治疗中获益的早期心衰患者。

核心结论

  • 糖尿病患者中利钠肽水平升高对未来心衰或死亡风险具有高度预后价值,支持开展NP筛查进行心衰风险评估。

研究设计与样本

  • 回顾性队列研究,查询Optum去标识化Market Clarity数据,纳入2017至2023年间接受门诊NP检测的≥18岁无已知心衰的1型或2型糖尿病成人。
  • 共纳入116,466例成人(1型糖尿病2,990例,2型糖尿病113,476例),随访至7年,54%为女性,中位年龄64岁,基线平均HbA1c 7.1%。
  • 采用多变量Cox比例风险模型评估NP水平与心衰发生或死亡的关联。

主要发现

  • 约39.6%的1型糖尿病患者和42.3%的2型糖尿病患者BNP≥50 pg/mL或NT-proBNP≥125 pg/mL。
  • 1型糖尿病中,与NT-proBNP<125 pg/mL相比,NT-proBNP 125-300 pg/mL的HR为2.04(95%CI 1.35-3.07),>300 pg/mL的HR为4.48(95%CI 3.11-6.47)。
  • 2型糖尿病中,与NT-proBNP<125 pg/mL相比,NT-proBNP 125-300 pg/mL的HR为1.85(95%CI 1.74-1.97),>300 pg/mL的HR为3.58(95%CI 3.39-3.78)。
  • BNP的观察结果与NT-proBNP相似。

临床怎么用

  • 对无已知心衰的1型或2型糖尿病患者,可考虑检测BNP或NT-proBNP以评估未来心衰或死亡风险。
  • NP水平升高(如NT-proBNP≥125 pg/mL)提示需进一步心衰评估和风险干预。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Heart failure (HF) is common in diabetes and may be asymptomatic in early stages. N-terminal pro-brain natriuretic peptide (NT-proBNP) and B-type natriuretic peptide (BNP) (collectively natriuretic peptides [NPs]) are markers that can be used to detect early HF in asymptomatic individuals who may benefit from disease-modifying therapies. We examined the prognostic role of NP levels in people with type 1 diabetes (T1D) or type 2 diabetes (T2D) without known HF. RESEARCH DESIGN AND METHODS: Optum's de-identified Market Clarity Data were queried for adults (aged ≥18 years) with T1D or T2D without known HF who received an outpatient NP test between 2017 and 2023. Associations between NP levels and incident HF or death were assessed using multivariable Cox proportional hazard models. RESULTS: Among 116,466 eligible adults (n = 2,990 with T1D; n = 113,476 with T2D) followed for up to 7 years (54% female; median age 64 years; mean HbA1c 7.1% at baseline), approximately 39.6% of individuals with T1D and 42.3% of individuals with T2D had BNP ≥50 pg/mL or NT-proBNP ≥125 pg/mL. In adjusted Cox models, increased NT-proBNP level was significantly associated with increased risk of incident HF or mortality among individuals with T1D (for NT-proBNP level 125-300 pg/mL: HR [95% CI] 2.04 [1.35-3.07], for NT-proBNP level >300 pg/mL: 4.48 [3.11-6.47], reference: NT-proBNP <125 pg/mL) and T2D (for NT-proBNP level 125-300 pg/mL: HR [95% CI] 1.85 [1.74-1.97], for NT-proBNP >300 pg/mL: 3.58 [3.39-3.78], reference: NT-proBNP <125 pg/mL). Similar findings were observed for BNP. CONCLUSIONS: Increased NP levels among individuals with diabetes are highly prognostic for future risk of HF or mortality. These findings support the implementation of NP screening for HF risk assessment in people with diabetes.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Pop-Busui R, Repetto E, Baron J, et al. Screening Natriuretic Peptide Levels Predicts Heart Failure and Death in Individuals With Type 1 and Type 2 Diabetes Without Known Heart Failure. Diabetes Care. 2025. PMID: 41166576. doi:10.2337/dc25-1260

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。